Co-Founder
Sheila Gujrathi, M.D. is a biotech entrepreneur, physician executive, translational scientist, and drug developer. Sheila currently serves as executive chair of the board of directors of Ventyx Biosciences and Lila Biologics and director of Janux Therapeutics. Sheila is also a co-founder of the Biotech CEO Sisterhood. Her prior roles include co-founder and CEO of Gossamer Bio, chair of Turning Point Therapeutics (acquired by Bristol Myers Squibb), venture advisor to Orbimed, CMO of Receptos (acquired by Celgene Corp.), and vice president of the global clinical development group in immunology at Bristol Myers Squibb. Sheila received both her M.D. in the accelerated Honors Program in medical education and her B.S. in biomedical engineering with highest distinction from Northwestern University. She completed her internal medicine internship and residency at Brigham and Women’s Hospital and Harvard Medical School and additional fellowship training in allergy and immunology at the University of California, San Francisco and Stanford University.